111 related articles for article (PubMed ID: 12840798)
1. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).
Hidalgo M; Bloedow D
Semin Oncol; 2003 Jun; 30(3 Suppl 7):25-33. PubMed ID: 12840798
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies with Erlotinib (Tarceva).
Akita RW; Sliwkowski MX
Semin Oncol; 2003 Jun; 30(3 Suppl 7):15-24. PubMed ID: 12840797
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib (Tarceva): an update on the clinical trial program.
Herbst RS
Semin Oncol; 2003 Jun; 30(3 Suppl 7):34-46. PubMed ID: 12840799
[TBL] [Abstract][Full Text] [Related]
4. Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?
Hortobagyi GN; Sauter G
Semin Oncol; 2003 Jun; 30(3 Suppl 7):47-53. PubMed ID: 12840800
[TBL] [Abstract][Full Text] [Related]
5. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib: preclinical investigations.
Hidalgo M
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):11-6. PubMed ID: 14682118
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Sandler A
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Rukazenkov Y; Speake G; Marshall G; Anderton J; Davies BR; Wilkinson RW; Mark Hickinson D; Swaisland A
Anticancer Drugs; 2009 Nov; 20(10):856-66. PubMed ID: 19657272
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Malik SN; Siu LL; Rowinsky EK; deGraffenried L; Hammond LA; Rizzo J; Bacus S; Brattain MG; Kreisberg JI; Hidalgo M
Clin Cancer Res; 2003 Jul; 9(7):2478-86. PubMed ID: 12855621
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
12. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
[TBL] [Abstract][Full Text] [Related]
13. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Siegel-Lakhai WS; Beijnen JH; Schellens JH
Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; Biddle A; Davis TH; Nugent WC; Memoli N; Hamilton M; Iwata KK; Rigas JR; Dmitrovsky E
Clin Cancer Res; 2004 Nov; 10(22):7547-54. PubMed ID: 15569985
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Herbst RS; Sandler A
Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
[TBL] [Abstract][Full Text] [Related]
16. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK
Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413
[TBL] [Abstract][Full Text] [Related]
17. Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Santarpia M; De Pas TM; Altavilla G; Spaggiari L; Rosell R
Future Oncol; 2013 Mar; 9(3):327-45. PubMed ID: 23469969
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Krozely P
Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
[TBL] [Abstract][Full Text] [Related]
19. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
Perez-Soler R
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4238s-4240s. PubMed ID: 15217965
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]